Lucid Group, Inc.

Lucid Group, Inc. (NASDAQ: LCID) is a vertically integrated technology and automotive company focused on developing, manufacturing, and distributing the next generation of electric vehicles (EVs), EV powertrains, and battery systems.

Key Highlights

• The company reported YoY decline of 30.54% in revenues to USD 232 thousand in Q3FY21 (ended September 30, 2021) compared to USD 334 thousand in Q3FY20.
• LCID's net loss expanded to USD 524.40 million during Q3FY21 vs. USD 161.24 million in Q3FY20.
• As of September 30, 2021, the company had cash and cash equivalents of USD 4.80 billion and total debt of USD 32.63 million.
• Its ROE in Q3FY21 was -20%, whereas the peer median stood at 1.8%.
• On November 05, 2021, LCID’s opened its latest retail location, the Lucid Studio at Tysons Corner Center in the Washington, DC, Metro Area. This location marks the 11th location of the growing network of Lucid Studios and furthers the company’s presence in the Eastern Seaboard area.
• Stock is currently trading above its crucial short-term (50-day) and long-term (200-day) SMA support levels, a bullish indicator.
• The stock is leaning towards the higher end of its 52-week range of USD 9.70 to USD 64.86.
• LCID's stock price has surged 120.41% and 148.13% in the past three and six months, respectively.

Technical Price Chart (as of November 23, 2021). Analysis by Kalkine

Conclusion: The company's top-line performance deteriorated in Q3FY21 compared to the previous comparable period, considering no visibility into profitability, technical indicators, and associated risks, we recommend a "Watch" rating on the stock at the current price of USD 50.36, down 1.49% as of November 23, 2021, 2:19 PM ET.

*The reference data in this report has been partly sourced from REFINITIV. 

Delta Air Lines, Inc.

Delta Air Lines, Inc. (NYSE: DAL) operates scheduled passenger and freight flights throughout the United States and worldwide. Its operating segments are Airline and Refinery. It also runs ancillary portfolio business, such as cargo business and Maintenance, Repair and Overhaul (MRO) operation.

 Key Highlights

• The company reported YoY growth of 198.95% in total operating revenues to USD 9.15 billion in Q3FY21 (ended September 30, 2021) compared to USD 3.06 billion in Q3FY20.
• DAL reported a net income of USD 1.21 billion in Q3FY21 vs. a net loss of USD 5.38 billion in Q3FY20.
• As of September 30, 2021, the company had cash and cash equivalents (including short-term investments) of USD 13.20 billion and total debt of USD 27.82 billion.
• Its net margin in Q3FY21 was 13.2%, whereas the peer median stood at 4.6%.
• High ROE of 62.4% in Q3FY21 vs. industry median of 3.4%.
• On November 03, 2021, VMO Aircraft Leasing, an aircraft leasing company based in San Francisco, signed a long-term lease agreement for two Airbus A350-900 aircraft with DAL. The delivery of the planes took place in October 2021.
• Stock is currently trading below its crucial short-term (50-day) and long-term (200-day) SMA support levels, a bearish indicator.
• The stock is currently leaning towards the lower band of its 52-week range of USD 37.31 to USD 52.28.
• DAL's stock price decreased 15.66% and 18.58% in the past six and nine months, respectively.

Technical Price Chart (as of November 23, 2021). Analysis by Kalkine

Conclusion: Considering the improvement in the top and bottom-line performance, technical indicators, and associated risks, we recommend a "Watch" rating on the stock at the current price of USD 39.36, down 1.03% as of November 23, 2021, 3:03 PM ET.

*The reference data in this report has been partly sourced from REFINITIV. 

Aurora Cannabis Inc.

Aurora Cannabis Inc. (NASDAQ: ACB) is a Canadian medical cannabis company engaged in the manufacturing, distribution, and sale of cannabis and cannabis-related products in Canada and overseas.

Key Highlights

• The company reported YoY decline of 11.07% in revenues to CAD 60.11 million in Q1FY22 (ended September 30, 2021) compared to CAD 67.59 million in Q1FY21.
• ACB's net loss reduced to CAD 11.88 million during Q1FY22 vs. CAD 101.39 million in Q1FY21.
• As of September 30, 2021, the company had cash and cash equivalents (including short-term investments) of CAD 375.27 million and total debt of CAD 406.78 million.
• Its net margin in Q1FY22 was -19.8%, whereas the peer median stood at 6.9%.
• On November 08, 2021, Aurora Nederland B.V., a wholly-owned indirect subsidiary of ACB, signed an agreement to invest in a significant equity stake in Growery B.V., a Netherlands-based license holder eligible to participate in the Controlled Cannabis Supply Chain Experiment (CCSC).
• Stock is currently trading below its crucial short-term (50-day) and long-term (200-day) SMA support levels, a bearish indicator.
• The stock is currently leaning towards the lower band of its 52-week range of USD 7.47 to USD 24.10.
• ACB's stock price has fallen 13.29% and 40.24% in the past six and nine months, respectively.

Technical Price Chart (as of November 23, 2021). Analysis by Kalkine

Conclusion: Considering the topline growth, no visibility into profitability, technical indicators, and associated risks, we recommend a "Watch" rating on the stock at the closing price of USD 6.63, down 1.04% as of November 23, 2021.

*The reference data in this report has been partly sourced from REFINITIV.

Disclaimer

The advice given by Kalkine Canada Advisory Services Inc. and provided on this website is general information only and it does not take into account your investment objectives, financial situation and the particular needs of any particular person. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people. The website www.kalkine.ca is published by Kalkine Canada Advisory Services Inc. The link to our Terms & Conditions has been provided please go through them. On the date of publishing this report (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.